Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Biocytogen Pharmaceuticals (Beijing) / Equity Capital Markets

Biocytogen, a China-based pre-clinical research and biopharmaceutical company, plans to raise up to USD 300m via a Hong Kong listing.We looked at the company's main business lines, including the gene-editing, pre-clinical pharmacology and efficacy evaluation, as well as the animal model selling. We note that the company has been expanding its business since its establishment in 2009, lately into the biopharmaceutical segment. Having said that, it remains a small player in respective fields of business. In addition to the pre-clinical business, we also look at its two core assets YH003 and YH001 briefly.Its pre-IPO investors are a mixed bag of domestic and international investors. Its management's experience is mainly related to the pre-clinical business and less for the biotech business.

Biocytogen, a China-based pre-clinical research and biopharmaceutical company, plans to raise up to USD 300m via a Hong Kong listing.We looked at the company's main business lines, including the gene-editing, pre-clinical pharmacology and efficacy evaluation, as well as the animal model selling. We note that the company has been expanding its business since its establishment in 2009, lately into the biopharmaceutical segment. Having said that, it remains a small player in respective fields of business. In addition to the pre-clinical business, we also look at its two core assets YH003 and YH001 briefly.Its pre-IPO investors are a mixed bag of domestic and international investors. Its management's experience is mainly related to the pre-clinical business and less for the biotech business.

Biocytogen (百奥赛图) Pre-IPO: From Animal CRO to Biotech

China

Biocytogen Pharmaceuticals Beijing Co., Ltd. operates as a biopharmaceutical and revenue generating pre clinical research services company. The Company produces mmunoglobulins, monoclonal antibodies, recombinant humanized antibodies, and others. Biocytogen Pharmaceuticals Beijing provides drug development, therapeutic antibody discovery and development, and other services.

Biocytogen Pharmaceuticals (Beijing) (2315 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocytogen (百奥赛图) Pre-IPO: From Animal CRO to Biotech

We look at Biocytogen's main business line of animal CRO (gene-edited mice) and also its two core assets YH003 and YH001.

Ke Yan, CFA, FRM